ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Allogene Therapeutics Inc

Allogene Therapeutics Inc (ALLO)

4.4688
0.0088
( 0.20% )
Updated: 14:53:37

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

ALLO News

Official News Only

ALLO Discussion

View Posts
Monksdream Monksdream 6 months ago
ALLO new 52 week low
👍️0
NY1972 NY1972 6 months ago
Yes. Signet-ring, TP53. ... dying. Even more aggressive than the ones enrolled in CART trial
👍️0
jondoeuk jondoeuk 6 months ago
Was that the case study (50-year-old female)?

I know the CAR-T is already in registrational trials both in China and the US. If all goes to plan, they expected to submit an NDA to the NMPA in 2024 and a BLA to the FDA in 2025. A next-gen version is in the clinic as well https://aacrjournals.org/clincancerres/article/26/20/5494/82735/Coexpression-of-IL7-and-CCL21-Increases-Efficacy

Also https://www.biospace.com/article/moderna-carsgen-join-forces-combining-mrna-cancer-vaccine-with-car-t/

However, it's getting pretty crowded
👍️0
NY1972 NY1972 6 months ago
$AFMD 24+ ATEZO was pretty effective (1/1) compared to CARThttps://t.co/WtuFoQNM37— Bon Wood (@ny1972_47) September 28, 2023
👍️0
jondoeuk jondoeuk 6 months ago
Upcoming https://www.globenewswire.com/news-release/2023/09/27/2750477/0/en/Allogene-Therapeutics-Announces-Three-Poster-Presentations-from-its-Next-Generation-AlloCAR-T-Platform-at-the-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting.html
👍️0
dmerc dmerc 8 months ago
short 49% Mentioned by Roensche Capital
👍️0
dmerc dmerc 8 months ago
https://www.benzinga.com/quote/ALLO/analyst-ratings
👍️0
jondoeuk jondoeuk 1 year ago
An oral presentation at AACR next month https://www.abstractsonline.com/pp8/#!/10828/presentation/10251
👍️0
jondoeuk jondoeuk 1 year ago
A proprietary approach to control rejection https://www.globenewswire.com/news-release/2022/11/10/2553356/0/en/Allogene-Therapeutics-Unveils-Novel-Approach-to-Generate-Engineered-AlloCAR-T-Cells-to-Control-Immune-Rejection-at-the-Annual-Meeting-of-the-Society-for-Immunotherapy-of-Cancer.html

This is one of a number of next-gen technologies being pioneered. Others, include https://www.globenewswire.com/en/news-release/2023/02/01/2599947/0/en/Allogene-Therapeutics-Presents-Data-on-Dagger-a-Next-Generation-AlloCAR-T-Platform-Technology.html
👍️0
jondoeuk jondoeuk 1 year ago
R&D showcase PR https://www.globenewswire.com/news-release/2022/11/29/2564467/0/en/Allogene-Therapeutics-R-D-Showcase-Features-Hematologic-and-Solid-Tumor-Advances-Across-its-AlloCAR-T-Platform.html

Slides https://ir.allogene.com/static-files/3eacf8bf-3cd0-47bc-a5ac-f5715083883a
👍️0
jondoeuk jondoeuk 2 years ago
ASGCT PR https://www.globenewswire.com/news-release/2022/05/19/2446950/0/en/Allogene-Therapeutics-Announces-Oral-Presentation-of-Pre-Clinical-Data-Highlighting-Improved-Anti-Tumor-Activity-of-Donor-Derived-Allogeneic-CAR-T-Cells-at-American-Society-of-Gene.html
👍️0
jondoeuk jondoeuk 2 years ago
New preclinical data https://aacrjournals.org/cancerrescommun/article/2/3/158/684708/Allogeneic-Anti-BCMA-CAR-T-Cells-Are-Superior-to
👍️0
jondoeuk jondoeuk 2 years ago
Additional data https://allogene.com/resources/download/ALPHA-Study.pdf https://allogene.com/resources/download/ALPHA2-Study.pdf https://allogene.com/resources/download/UNIVERSAL-Updated-Phase-1-Data-Validates-Feasibility-Allogeneic.pdf
https://ir.allogene.com/static-files/891ef05d-ff61-4c95-9a55-9ff7a515102d
👍️0
jondoeuk jondoeuk 2 years ago
AS PR's https://www.globenewswire.com/news-release/2021/12/13/2350984/0/en/Allogene-Therapeutics-Reports-Positive-Results-from-Phase-1-UNIVERSAL-Study-of-Single-Dose-ALLO-715-AlloCAR-T-Cell-Therapy-in-Relapsed-Refractory-Multiple-Myeloma-at-the-63rd-Ameri.html

https://www.globenewswire.com/news-release/2021/12/13/2350962/0/en/Allogene-Therapeutics-Reports-Positive-Phase-1-Data-from-the-ALPHA-Trials-in-Non-Hodgkin-s-Lymphoma-at-the-63rd-Annual-Meeting-of-the-American-Society-of-Hematology.html
👍️0
jondoeuk jondoeuk 2 years ago
Abstracts

ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing https://ash.confex.com/ash/2021/webprogram/Paper146045.html

ALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma Comparable to Autologous CAR T https://ash.confex.com/ash/2021/webprogram/Paper146038.html

Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma https://ash.confex.com/ash/2021/webprogram/Paper145572.html
👍️0
jondoeuk jondoeuk 2 years ago
ASH data https://www.globenewswire.com/news-release/2021/11/04/2327658/0/en/Allogene-Therapeutics-to-Showcase-Clinical-Data-from-the-ALPHA-ALPHA2-and-UNIVERSAL-AlloCAR-T-Trials-at-the-63rd-Annual-Meeting-of-the-American-Society-of-Hematology.html
👍️0
makinezmoney makinezmoney 2 years ago
$ALLO: 2nd day of bouncing off bottom...... now $17.25



GO $ALLO
👍️0
jondoeuk jondoeuk 3 years ago
New PR https://www.globenewswire.com/news-release/2021/06/04/2242102/0/en/Allogene-Therapeutics-Presents-Positive-Phase-1-Data-on-ALLO-501-and-ALLO-501A-in-Relapsed-Refractory-Non-Hodgkin-Lymphoma-at-the-2021-Annual-Meeting-of-the-American-Society-of-Cli.html

Posters https://www.allogene.com/resources/download/First-In-Human-Data-of-ALLO-501A.pdf https://www.allogene.com/resources/download/Safety-and-PK-PD-of-ALLO-647.pdf
👍️0
conix conix 3 years ago
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at Truist Securities from a "hold" rating to a "buy" rating. They now have a $41.00 price target on the stock, up previously from $34.00.This represents a 64.3% upside from the current price of $24.96.
👍️0
jondoeuk jondoeuk 3 years ago
The PR https://www.globenewswire.com/news-release/2021/05/19/2232864/0/en/Allogene-Therapeutics-CD19-Forum-Highlights-Positive-Results-from-Phase-1-Studies-of-ALLO-501-and-ALLO-501A-in-Relapsed-Refractory-Non-Hodgkin-Lymphoma-and-Plan-to-Initiate-Pivotal.html

Slides https://ir.allogene.com/static-files/7a26a1c0-55f9-4474-a362-9a49b598c43c
👍️0
jondoeuk jondoeuk 3 years ago
The poster https://www.allogene.com/resources/download/AACR-2021-PD1-iTurboCAR.pdf
👍️0
jondoeuk jondoeuk 3 years ago
Link to the webcast https://allogene.zoom.us/webinar/register/WN_nyDYMLTnR9yi19rJRu-1kA
👍️0
jondoeuk jondoeuk 3 years ago
Longer term data from the ALLO-501 PhI (ALPHA) trial will be presented alongside initial data from the PhI ALLO-501A (ALPHA2) trial at ASCO. There will be a separate presentation on ALLO-647, to include safety and PK/PD data

ALLO-501A, is intended for a potentially pivotal PhII trial, which should start in 2H, Previously it has been granted FDA fast track for R/R DLBCL. The company will host a webcast to review the data sets on May 19, at 2:30 pm PT/5:30 pm ET.
👍️0
jondoeuk jondoeuk 3 years ago
An internal program (to overcome rejection) will downregulating MHC Class I expression and adding an NK cell inhibitory receptor antibody. Also, improvements are being made to the ex vivo expansion, with the use of defined populations of T-cells, of certain phenotypes (this achieved with cytokines and/or an anti-CD3/CD28 nanomatrix). In addition, RNAi to inhibit certain activity, such as EBAG9, which increases the release of cytolytic granules and/or granzyme- containing secretory lysosomes.
👍️0
jondoeuk jondoeuk 3 years ago
From AACR:

CAR T cell therapy has attained unprecedented success in the treatment of hematological malignancies. However, clinical benefit in solid tumor indications has been limited, potentially in part due to suppressive solid tumor microenvironments (TME) that inhibit T cell effector function and persistence. While the provision of cytokine support can help CAR T cells overcome suppressive TME, combining CAR T therapy with systemically-administered cytokines/cytokine mimetics can result in toxicities and locally secreted cytokines may enhance rejection of allogeneic cell products by host cells. For this reason we had previously designed and tested a novel cytokine-stimulated CAR T cell designated TurboCARs. TurboCAR T cells coexpress a CAR and a Turbo domain (i.e. a homodimeric cytokine receptor chimera) that transmits CAR T cell-intrinsic cytokine signals, resulting in enhanced potency, expansion and persistence in preclinical studies. However, TurboCAR T cells may remain sensitive to inhibition by immune barriers, such as negative signaling through the PD1 receptor. We reasoned that a two-pronged approach aimed at inhibiting immune-suppressive PD1 signaling while simultaneously transmitting immune-potentiating cytokine signaling may augment CAR T cell activity in solid tumors. To this end, we engineered PD1 TurboCAR T cells, in which the Turbo domain is fused to a PD1 ectodomain that serves as a dominant-negative receptor. The PD1 ectodomain was further modified for high-affinity binding to PD1 ligands, allowing for preferential ligand sequestration and more effective inhibition of endogenous PD1 signaling. Despite having a larger lentiviral vector cargo, PD1 TurboCAR T cell products remained manufacturable and retained a favorable memory phenotype. PD1 TurboCAR T cells directed towards PDL1-expressing solid tumor target cells showed increased functionality compared to CAR T cells combined with PD1 blockade or to the parental TurboCAR T cells alone. In conclusion, PD1 TurboCARs augmented with a PD1 dominant negative ectodomain conferred CAR T cells with resistance to PD1-mediated inhibition, while simultaneously transmitting cytokine signals in a CAR T cell-intrinsic fashion. As an all-in-one product, PD1 TurboCAR T cells may obviate the need for combination therapy with anti-PD1 antibodies, while circumventing safety risks associated with systemic cytokine administration.

https://www.abstractsonline.com/pp8/#!/9325/presentation/2621
👍️0
jondoeuk jondoeuk 3 years ago
From the recent call, ALLO have disclosed they are already designing next-gen TurboCARs to overcome immunosuppressive TMEs, particularly in solid tumours by engineering T-cell stimulatory domains that are activated by certain factors, such as PD-L1 and TGFb. Also, in concert with Baylor College of Medicine, are exploring the use of alloimmune defense receptors (to overcome rejection) [1].

Other planned improvements include manufacturing and CAR engineering. On top of this, there are twelve solid tumour targets, with two (CD70 [2,3] and DLL3 [4,5]) disclosed.

Refs:
1 https://www.nature.com/articles/s41587-020-0601-5
2 https://www.allogene.com/resources/download/AlloCAR-T-Targeting-CD70-For-RCC.pdf
3 https://www.mdpi.com/2072-6694/11/10/1611/htm
4 https://www.allogene.com/resources/download/Screening-and-Characterization-of-AlloCAR-T.pdf
5 https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.TPS2597
👍️0
jondoeuk jondoeuk 3 years ago
Preclinical data (ASH) https://ashpublications.org/blood/article/136/Supplement%201/8/472830/Preclinical-Evaluation-of-ALLO-605-an-Allogeneic
👍️0

Your Recent History

Delayed Upgrade Clock